Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of GW572016 and Tamoxifen in Patients With Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen

NCT00118157 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00118157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00118157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of GW572016 and Tamoxifen in Patients With Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2005
Completion date
September 30, 2014
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor positive, male breast carcinoma, progesterone receptor positive, recurrent breast carcinoma, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer